Please Wait
Applying Filters...
menu
    • menu
    Aspen API. More than just an API™

    Virtual Booth

    Contact Supplier

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Laboratorium Ofichem, offering a flexible, high-tech environment to produce broad range of APIs for Human & Vet pharmaceutical markets.

    Virtual Booth

    Contact Supplier

    Menu

    Crofelemer

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 7,823Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Jaguar Health Seeks EU Approval for Canalevia for Dog Diarrhea
    Jaguar Health Seeks EU Approval for Canalevia for Dog Diarrhea

    25 Jun 2025

    // ACCESSWIRE

    https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/jaguar-health-to-pursue-approval-of-canalevia-in-european-union-for-t-1042839

    ACCESSWIRE
    25 Jun 2025
    Share Share
    Jaguar Health Extends Maturity Date of Convertible Notes to Jan
    Jaguar Health Extends Maturity Date of Convertible Notes to Jan

    24 Jun 2025

    // ACCESSWIRE

    https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/jaguar-health-announces-extension-of-the-maturity-date-of-its-convert-1042603

    ACCESSWIRE
    24 Jun 2025
    Share Share
    Jaguar Starts Phase 2 Trial of Crofelemer for Pediatric MVID
    Jaguar Starts Phase 2 Trial of Crofelemer for Pediatric MVID

    20 May 2025

    // ACCESSWIRE

    https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/first-patient-randomized-in-jaguar-healths-phase-2-randomized-double-1029830

    ACCESSWIRE
    20 May 2025
    Share Share
    Jaguar Health Provides Overview of Crofelemer-Related Catalysts
    Jaguar Health Provides Overview of Crofelemer-Related Catalysts

    07 May 2025

    // ACCESSWIRE

    https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/jaguar-health-provides-overview-of-2025-crofelemer-related-catalysts-1024559

    ACCESSWIRE
    07 May 2025
    Share Share
    Crofelemer Shows Benefit in Rare Bowel Disorders
    Crofelemer Shows Benefit in Rare Bowel Disorders

    30 Apr 2025

    // ACCESSWIRE

    https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/proof-of-concept-results-show-crofelemer-reduced-total-parenteral-nut-1021550

    ACCESSWIRE
    30 Apr 2025
    Share Share
    Jaguar to Share Crofelemer Study Data in April 30 Webcast
    Jaguar to Share Crofelemer Study Data in April 30 Webcast

    29 Apr 2025

    // ACCESSWIRE

    https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/reminder-jaguar-health-hosting-april-30-investor-webcast-to-present-i-1021431

    ACCESSWIRE
    29 Apr 2025
    Share Share